EA202190626A3 - Комбинация тразодона и габапентина для лечения боли - Google Patents

Комбинация тразодона и габапентина для лечения боли

Info

Publication number
EA202190626A3
EA202190626A3 EA202190626A EA202190626A EA202190626A3 EA 202190626 A3 EA202190626 A3 EA 202190626A3 EA 202190626 A EA202190626 A EA 202190626A EA 202190626 A EA202190626 A EA 202190626A EA 202190626 A3 EA202190626 A3 EA 202190626A3
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
trazodone
gabapentin
pain treatment
salt
Prior art date
Application number
EA202190626A
Other languages
English (en)
Other versions
EA202190626A2 (ru
Inventor
Беатриче Гарроне
Лючия Дурандо
Фабрицио Калисти
Original Assignee
Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. filed Critical Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А.
Publication of EA202190626A2 publication Critical patent/EA202190626A2/ru
Publication of EA202190626A3 publication Critical patent/EA202190626A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции, включающей комбинацию тразодона или его соли и габапентина или его соли или пролекарства, указанная комбинация имеет синергический эффект в лечении боли.
EA202190626A 2015-10-22 2016-10-17 Комбинация тразодона и габапентина для лечения боли EA202190626A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15191024 2015-10-22

Publications (2)

Publication Number Publication Date
EA202190626A2 EA202190626A2 (ru) 2021-06-30
EA202190626A3 true EA202190626A3 (ru) 2021-09-30

Family

ID=54345445

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202190626A EA202190626A3 (ru) 2015-10-22 2016-10-17 Комбинация тразодона и габапентина для лечения боли
EA201890911A EA037838B1 (ru) 2015-10-22 2016-10-17 Комбинация тразодона и габапентина для лечения боли

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201890911A EA037838B1 (ru) 2015-10-22 2016-10-17 Комбинация тразодона и габапентина для лечения боли

Country Status (27)

Country Link
US (2) US10786498B2 (ru)
EP (2) EP3881845A3 (ru)
JP (1) JP6924184B2 (ru)
KR (1) KR20180063314A (ru)
CN (1) CN108174599B (ru)
AR (1) AR106415A1 (ru)
AU (1) AU2016341063B2 (ru)
BR (1) BR112018007374B1 (ru)
CA (1) CA2999389C (ru)
CY (1) CY1124229T1 (ru)
DK (1) DK3364975T3 (ru)
EA (2) EA202190626A3 (ru)
ES (1) ES2879392T3 (ru)
GE (1) GEP20207145B (ru)
HK (1) HK1252359A1 (ru)
HR (1) HRP20210832T1 (ru)
HU (1) HUE054653T2 (ru)
IL (1) IL258316B (ru)
LT (1) LT3364975T (ru)
MD (1) MD3364975T2 (ru)
MX (1) MX2018004532A (ru)
PL (1) PL3364975T3 (ru)
PT (1) PT3364975T (ru)
RS (1) RS61989B1 (ru)
SI (1) SI3364975T1 (ru)
UA (1) UA122245C2 (ru)
WO (1) WO2017067870A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900006602A1 (it) * 2019-05-07 2020-11-07 Acraf Composizione farmaceutica per il trattamento del dolore neuropatico
EP3907214A1 (en) * 2020-05-04 2021-11-10 Dompe' Farmaceutici S.P.A. Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06002789A (es) 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
EP1675582A1 (en) * 2003-09-12 2006-07-05 Warner-Lambert Company LLC Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
US20080096872A1 (en) * 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
US20120083508A1 (en) * 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
JP5328787B2 (ja) * 2007-07-18 2013-10-30 ダウ グローバル テクノロジーズ エルエルシー 水−グリコール液圧流体組成物
US10300031B2 (en) 2007-08-06 2019-05-28 Trinity Laboratories Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
TW201006789A (en) * 2008-07-02 2010-02-16 Teva Pharma Gabapentin enacarbil salts and processes for their preparation
EP2727473A4 (en) 2011-06-28 2015-05-06 Vivozon Inc COMBINATION OF EFFICIENT SUBSTANCES WITH SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF

Also Published As

Publication number Publication date
AR106415A1 (es) 2018-01-10
GEP20207145B (en) 2020-08-25
RS61989B1 (sr) 2021-07-30
WO2017067870A1 (en) 2017-04-27
CY1124229T1 (el) 2022-05-27
EP3364975A1 (en) 2018-08-29
LT3364975T (lt) 2021-09-10
MD3364975T2 (ro) 2021-09-30
CA2999389C (en) 2023-12-19
HRP20210832T1 (hr) 2021-08-06
PL3364975T3 (pl) 2021-11-02
PT3364975T (pt) 2021-05-27
EA202190626A2 (ru) 2021-06-30
AU2016341063A1 (en) 2018-04-26
AU2016341063B2 (en) 2022-04-14
US20200316060A1 (en) 2020-10-08
EP3881845A3 (en) 2021-09-29
SI3364975T1 (sl) 2021-08-31
UA122245C2 (uk) 2020-10-12
KR20180063314A (ko) 2018-06-11
BR112018007374B1 (pt) 2023-11-28
HK1252359A1 (zh) 2019-05-24
CN108174599B (zh) 2021-09-03
EA037838B1 (ru) 2021-05-26
IL258316A (en) 2018-06-28
JP2018531259A (ja) 2018-10-25
DK3364975T3 (da) 2021-06-21
CN108174599A (zh) 2018-06-15
MX2018004532A (es) 2018-09-12
US11752147B2 (en) 2023-09-12
US20180296553A1 (en) 2018-10-18
ES2879392T3 (es) 2021-11-22
US10786498B2 (en) 2020-09-29
EP3881845A2 (en) 2021-09-22
IL258316B (en) 2022-08-01
EA201890911A1 (ru) 2018-09-28
CA2999389A1 (en) 2017-04-27
BR112018007374A2 (pt) 2018-10-23
EP3364975B1 (en) 2021-04-07
JP6924184B2 (ja) 2021-08-25
HUE054653T2 (hu) 2021-09-28

Similar Documents

Publication Publication Date Title
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201890204A1 (ru) Антибактериальные соединения
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691582A1 (ru) Новые фармацевтические препараты
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201692480A1 (ru) Фармацевтическая композиция
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201692470A1 (ru) Фармацевтические комбинации
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201791174A1 (ru) Антимикотическое соединение
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA201691896A1 (ru) Соединения и способы их применения